ALX ONCOLOGY HOLDINGS INC
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Phone 650-466-7125
Fiscal Year End 1231
EIN 850642577
Financial Overview
FY2024
-$123.48M
Net Income
$242.55M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 9, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 6, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
Insider Trading
BUY 2 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.